A urology email list is a verified database of licensed urologists, urogynecologists, and pediatric urologists, built from conference and CME partnerships, state and national medical associations, healthcare publication networks, and B2B2C matching and verification programs. SparkDBi maintains 14,187 verified US urology contacts across 3 subspecialties.
Trusted by Revenue and Data Teams at
SparkDBi maintains a verified urology email list covering 14,187 urologists, urogynecologists, and pediatric urologists across the United States. Every contact is sourced from conference and CME partnerships, state and national professional associations, and healthcare publication networks, then validated through email inbox verification, phone validation, and physical address confirmation before delivery. The database refreshes monthly.
Urology sits at the intersection of two of the most commercially active drug categories in pharma: urological oncology (prostate cancer, bladder cancer, kidney cancer) and lower urinary tract conditions (BPH, OAB, erectile dysfunction). For device companies, robotic surgery systems, endoscopy equipment, and stone management technology all target the urologist population directly.
Who Uses the Urology Email List
Pharmaceutical companies with prostate cancer pipelines are the largest buyer category. Abiraterone, enzalutamide, darolutamide, and apalutamide all target castration-resistant prostate cancer patients managed primarily by urologists. PARP inhibitors (olaparib, rucaparib, niraparib) for HRR-mutated prostate cancer have added a targeted therapy layer requiring ongoing urologist engagement. The volume of active prostate cancer drug programs makes urology one of the highest-demand HCP data requests in pharma.
Bladder cancer drug companies use the urology list for outreach to urologists who identify, diagnose, and manage urothelial carcinoma. Checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab) and antibody-drug conjugates (enfortumab vedotin) have transformed the treatment landscape for locally advanced and metastatic bladder cancer, creating new prescribing patterns and commercial education needs at the urologist level.
Kidney cancer (renal cell carcinoma) programs target urologists and medical oncologists jointly. TKIs (sunitinib, axitinib, cabozantinib) and combination immunotherapy regimens (nivolumab plus ipilimumab, pembrolizumab plus axitinib) require urologist involvement in diagnosis and early treatment decisions, particularly for surgical candidates considering cytoreductive nephrectomy.
BPH and OAB drug companies use the urology list for outreach to the high-volume community urologist population managing alpha blockers, 5-alpha reductase inhibitors, antimuscarinics, and beta-3 agonists. Tamsulosin, dutasteride, mirabegron, vibegron, fesoterodine, and tadalafil are all active in the BPH/OAB market with ongoing brand competition for urologist prescribing decisions.
Medical device companies use the list for outreach to urologists who select and operate robotic surgery systems (Intuitive Surgical da Vinci), cystoscopy and ureteroscopy equipment (Karl Storz, Olympus), lithotripters (ESWL systems), prostate therapy systems (GreenLight laser XPS, HIFU, Rezum), and ureteral stenting systems.
Request Urology Contact Data
Subspecialty filters, geography, sample records available
Urology Subspecialties and Verified Contacts
The SparkDBi urology database covers 3 subspecialty classifications. All three are available as individual segments or in a combined file. The urologist general category covers the full scope of urological practice including oncology, stones, BPH, OAB, male fertility, and functional urology.
| Subspecialty | Provider Type | Contacts |
|---|---|---|
| Urologist | Physician | 10,653 |
| Urogynecologist | Physician | 566 |
| Pediatrics - Urologist | Physician | 228 |
Key Drugs and Devices in Urology
Urological oncology drugs represent the highest commercial activity within the urology prescriber audience. Key categories include androgen deprivation therapy (leuprolide, goserelin, degarelix), second-generation anti-androgens (enzalutamide, abiraterone, darolutamide, apalutamide), PARP inhibitors (olaparib, rucaparib, niraparib) for prostate cancer, checkpoint inhibitors for bladder and renal cell carcinoma, and ADCs (enfortumab vedotin for bladder cancer). Each category requires targeted urologist outreach at the community and academic level.
Lower urinary tract drugs targeting BPH and OAB include alpha blockers (tamsulosin, alfuzosin, silodosin), 5-alpha reductase inhibitors (dutasteride, finasteride), beta-3 agonists (mirabegron, vibegron), antimuscarinics (oxybutynin, tolterodine, fesoterodine, solifenacin), and PDE5 inhibitors (tadalafil) for BPH. These categories have large prescribing populations and ongoing brand switching patterns making urologist outreach commercially valuable.
Urological devices include robotic surgery systems (da Vinci for radical prostatectomy and partial nephrectomy), flexible ureteroscopes for stone management, external shock wave lithotripsy (ESWL) systems, laser systems for BPH (GreenLight XPS, Holmium laser), HIFU systems (Sonablate, Focal One), penile prostheses (AMS 700, Coloplast Titan), artificial urinary sphincters (AMS 800), and MRI-guided prostate biopsy systems. Each device category requires outreach to a defined urologist audience with appropriate volume and case mix.
How SparkDBi Sources and Verifies HCP Data
SparkDBi builds its HCP contact database from multiple vetted channels. Primary sources include conference attendance and CME event participation records from healthcare education partners, member directories from state and national professional associations, subscriber and contributor lists from healthcare publication networks, and B2B2C data matching and verification partnerships.
Publicly available sources including CMS and NPPES records are used as a cross-reference and comparison tool only. They are not a primary data source. CMS and NPPES data is frequently stale or out of date for direct contact purposes. SparkDBi treats it as one reference point among many rather than a source of record.
Verification runs across three dimensions. Email inbox verification connects directly to the receiving mail server and confirms the specific mailbox accepts incoming messages, without sending a message. Phone validation confirms work phone numbers are active and matched to the provider record. Physical address validation covers both work practice addresses and home addresses, with records that fail validation removed and replaced in the next monthly refresh cycle.
NPI Taxonomy Codes for Urology
CMS NPI taxonomy codes for reference. These are useful when specifying subspecialty requirements or independently verifying provider credentials.
| Taxonomy Code | Urology Classification |
|---|---|
| 208800000X | Urology (General) |
Unlike cardiology or neurology, CMS does not assign separate NPI taxonomy codes for most urological subspecialties. SparkDBi further segments the urology database using practice type indicators, hospital affiliation, and procedure volume data to identify subspecialty focus areas such as oncological urology, endourology, female pelvic medicine, and pediatric urology.
Practice Setting Breakdown
Urology has one of the highest rates of private group practice among surgical specialties. About 55% of urologists in the SparkDBi database practice in private urology groups or multispecialty groups with urology divisions. The remaining 45% are hospital-employed or academic. This split is meaningful for device companies since private-practice urologists in surgical centers often have more autonomous implant and equipment selection authority.
Top 10 Hospitals for Urology (2026 World Rankings)
Rankings from the Newsweek World's Best Specialized Hospitals 2026 report. SparkDBi maintains verified contact data for urologists affiliated with each institution.
| Rank | Hospital | Location |
|---|---|---|
| #1 | Cleveland Clinic | Cleveland, US |
| #2 | Seoul National University Hospital | Seoul, KR |
| #3 | Mayo Clinic - Rochester | Rochester, US |
| #4 | The Johns Hopkins Hospital | Baltimore, US |
| #5 | Memorial Sloan Kettering Cancer Center | New York City, US |
| #6 | Asan Medical Center | Seoul, KR |
| #7 | University College Hospital | London, UK |
| #8 | Guy's Hospital | London, UK |
| #9 | MD Anderson Cancer Center | Houston, US |
| #10 | Samsung Medical Center | Seoul, KR |
Geographic and International Coverage
The US urology database covers all 50 states. Highest concentrations are in California, Texas, Florida, New York, and Illinois. International urology data is available for the UK, South Korea, Germany, Canada, and Australia. Contact SparkDBi for current international counts.
Deliverability and Inbox Placement
Urologists in hospital-employed or academic settings use enterprise email environments with standard filtering. Private-practice urologists in group and ASC settings use practice-domain email with lighter filtering, generally producing better inbox rates for commercial outreach. SparkDBi flags enterprise vs independent domains in delivered datasets.
Data Enrichment and Available Fields
For existing urology contact lists, SparkDBi can append or verify NPI numbers, hospital affiliations, email addresses, practice addresses, and license status. Match rates average 75% against the full database.
Compliance
The SparkDBi urology email list contains no patient data. All records are professional contact information for licensed urology providers. The database is HIPAA-aligned, CAN-SPAM compliant, and CCPA-aware. Business Associate Agreements are available on request.